These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 20078617)

  • 1. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.
    Kohlrausch FB; de Cássia Estrela R; Barroso PF; Suarez-Kurtz G
    Br J Clin Pharmacol; 2010 Jan; 69(1):95-8. PubMed ID: 20078617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
    Rakhmanina NY; Neely MN; Van Schaik RH; Gordish-Dressman HA; Williams KD; Soldin SJ; van den Anker JN
    Ther Drug Monit; 2011 Aug; 33(4):417-24. PubMed ID: 21743379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy.
    Estrela Rde C; Ribeiro FS; Barroso PF; Tuyama M; Gregório SP; Dias-Neto E; Struchiner CJ; Suarez-Kurtz G
    Pharmacogenomics; 2009 Feb; 10(2):311-8. PubMed ID: 19207033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.
    Schipani A; Egan D; Dickinson L; Davies G; Boffito M; Youle M; Khoo SH; Back DJ; Owen A
    Antivir Ther; 2012; 17(5):861-8. PubMed ID: 22477766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.
    Hartkoorn RC; Kwan WS; Shallcross V; Chaikan A; Liptrott N; Egan D; Sora ES; James CE; Gibbons S; Bray PG; Back DJ; Khoo SH; Owen A
    Pharmacogenet Genomics; 2010 Feb; 20(2):112-20. PubMed ID: 20051929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.
    Zhang X; Tierney C; Albrecht M; Demeter LM; Morse G; DiFrancesco R; Dykes C; Jiang H; Haas DW
    Ther Drug Monit; 2013 Apr; 35(2):209-16. PubMed ID: 23503447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.
    Liu X; Ma Q; Zhao Y; Mu W; Sun X; Cheng Y; Zhang H; Ma Y; Zhang F
    Pharmacotherapy; 2017 Sep; 37(9):1073-1080. PubMed ID: 28718515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects.
    Estrela RC; Santoro AB; Barroso PF; Tuyama M; Suarez-Kurtz G
    Clin Pharmacol Ther; 2008 Aug; 84(2):205-7. PubMed ID: 18288082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
    Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
    Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.
    Calza L; Mosca L; Pocaterra D; Piergentili B; Colangeli V; Manfredi R; Erario A; Grossi G; Verucchi G; Viale P
    Eur J Clin Pharmacol; 2011 Feb; 67(2):143-9. PubMed ID: 20878151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.
    Pasanen MK; Backman JT; Neuvonen PJ; Niemi M
    Eur J Clin Pharmacol; 2006 Jun; 62(6):409-15. PubMed ID: 16758257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
    Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
    Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
    Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
    Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of SLCO1B1 polymorphisms on lopinavir C
    Dragović G; Dimitrijević B; Kušić J; Soldatović I; Jevtović D; Olagunju A; Owen A
    Br J Clin Pharmacol; 2020 Jul; 86(7):1289-1295. PubMed ID: 32022294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.
    Olagunju A; Schipani A; Siccardi M; Egan D; Khoo S; Back D; Owen A
    Pharmacogenet Genomics; 2014 Sep; 24(9):459-63. PubMed ID: 24950369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations.
    Gutiérrez F; Padilla S; Masiá M; Navarro A; Gallego J; Hernández I; Ramos JM; Martin-Hidalgo A
    Antivir Ther; 2004 Feb; 9(1):105-13. PubMed ID: 15040542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
    Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
    Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
    Lubomirov R; di Iulio J; Fayet A; Colombo S; Martinez R; Marzolini C; Furrer H; Vernazza P; Calmy A; Cavassini M; Ledergerber B; Rentsch K; Descombes P; Buclin T; Decosterd LA; Csajka C; Telenti A;
    Pharmacogenet Genomics; 2010 Apr; 20(4):217-30. PubMed ID: 20139798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians.
    Sortica VA; Fiegenbaum M; Lima LO; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
    Clin Chem Lab Med; 2012 Mar; 50(3):441-8. PubMed ID: 22505549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.
    Lambert JS; Else LJ; Jackson V; Breiden J; Gibbons S; Dickinson L; Back DJ; Brennan M; Connor EO; Boyle N; Fleming C; Coulter-Smith S; Khoo SH
    HIV Med; 2011 Mar; 12(3):166-73. PubMed ID: 20726906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.